• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Merck's HPV Vaccine Effective Against 9 Subtypes

Article

The study, conducted in Austria, evaluated the potency of the 9-valent vaccine in preventing the development of cervical precancer in women infected with HPV.

An experimental vaccine meant to protect against 9 types of human papillomavirus (HPV) could prevent 90 percent of all cervical cancers, a new study suggests.

Researchers examined data from more than 2,500 women with precancerous cervical lesions and found that nearly all were caused by the nine types of HPV targeted by the vaccine being developed by Merck and Co.

Cancer Epidemiology, Biomarkers & Prevention

The new vaccine, currently undergoing clinical trials, protects against more types of HPV than current vaccines, according to the study published Oct. 1 in the journal .

Report on MedicalXpress: http://bit.ly/1rMstbg

Related Videos
Mila Felder, MD, FACEP
Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute (FCS)
Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance (COA) and physician and partner of AO Multispecialty Clinic in Augusta, Georgia.
Dr Lucy Langer
Edward Arrowsmith, MD, MPH
Dr Kathi Mooney
Tiago Biachi de Castria, MD, PhD, Moffitt Cancer Center
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.